Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): A review
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
One of the greatest national security threats to the United States is the detonation of an improvised nuclear device or a radiological dispersal device in a heavily populated area. As such, this type of security threat is considered to be of relatively low risk, but one that would have an extraordinary high impact on health and well-being of the US citizenry. Psychological counseling and medical assessments would be necessary for all those significantly impacted by the nuclear/radiological event. Direct medical interventions would be necessary for all those individuals who had received substantial radiation exposures (e.g., >1 Gy). Although no drugs or products have yet been specifically approved by the United States Food and Drug Administration (US FDA) to treat the effects of acute radiation syndrome (ARS), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), and pegylated G-CSF have been used off label for treating radiation accident victims. Recent threats of terrorist attacks using nuclear or radiologic devices makes it imperative that the medical community have up-to-date information and a clear understanding of treatment protocols using therapeutically effective recombinant growth factors and cytokines such as G-CSF and GM-CSF for patients exposed to injurious doses of ionizing radiation. Based on limited human studies with underlying biology, we see that the recombinants, G-CSF and GM-CSF appear to have modest, but significant medicinal value in treating radiation accident victims. In the near future, the US FDA may approve G-CSF and GM-CSF as ‘Emergency Use Authorization’ (EUA) for managing radiation-induced aplasia, an ARS-related pathology. In this article, we review the status of growth factors for the treatment of radiological/nuclear accident victims.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Waselenko, J. K., MacVittie, T. J., Blakely, W. F., Pesik, N., Wiley, A. L., Dickerson, W. E., Tsu, H., Confer, D. L., Coleman, C. N., Seed, T., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-12-200406150-00015 · Cited by 766 · cited 2×
“The use of growth factors in treating victims in a radiation-exposure scenario is rationalized based on the following three facts: (a) improved survival in irradiated animals (mice, canines, minipigs, and NHPs), (b) improved neutrophil recovery in cancer patients-treated with growth factors, and (c) an observed dimini…”
BackgroundInfluentialSelf-citationFilgrastim improves survival in lethally irradiated nonhuman primates
Farese, A. M., Cohen, M. V., Katz, B. P., Smith, C. P., Gibbs, A., Cohen, D. M., & MacVittie, T. J. (2013) · Radiation Research · doi:10.1667/rr3049.1 · Cited by 187
Use of recombinant granulocyte-macrophage colony stimulating factor in the Brazil radiation accident
Butturini, A., Gale, R., Lopes, D., Cunha, C., Ho, W., Sanpai, J., De Souza, P., Cordiero, J., Neto, C., De Souza, C., et al. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90121-3 · Cited by 113
Moroni, M., Ngudiankama, B. F., Christensen, C., Olsen, C. H., Owens, R., Lombardini, E. D., Holt, R. K., & Whitnall, M. H. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.04.041 · Cited by 64
Efficacy of radiation countermeasures depends on radiation quality
Cary, L. H., Ngudiankama, B. F., Salber, R. E., Ledney, G. D., & Whitnall, M. H. (2012) · Radiation Research · doi:10.1667/rr2783.1 · Cited by 41
First use of myeloid colony-stimulating factors in humans
Gale, R. P., & Vorobiov, A. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.57 · Cited by 16
Cited by
Animal models for acute radiation syndrome drug discovery
Singh, V. K., Newman, V. L., Berg, A. N., & MacVittie, T. J. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1023290 · Cited by 139
“G-CSF and GM-CSF fall under this category [15].”
BackgroundInfluentialSelf-citationSingh, V. K., & Seed, T. M. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1969054 · Cited by 88
Self-citationBunin, D. I., Bakke, J., Green, C. E., Javitz, H. S., Fielden, M., & Chang, P. Y. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1605465 · Cited by 60
“These three approved cytokines address post-radiation neutropenia (low neutrophil counts) and the increased risk of infection and febrile neutropenia (Waselenko et al. 2004; Singh et al. 2015) but do not address thrombocytopenia (low platelet counts) and excessive bleeding that also occurs in H-ARS.”
BackgroundZhong, Y., Pouliot, M., Downey, A.-M., Mockbee, C., Roychowdhury, D., Wierzbicki, W., & Authier, S. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1673499 · Cited by 52
“However, until recently, there were limited data to inform use of LGFs following a nuclear incident and no U.S. Food and Drug Administration (FDA) approved LGF medical countermeasures (MCM) (Singh et al. 2015).”
BackgroundInfluentialClayton, N. P., Khan-Malek, R. C., Dangler, C. A., Zhang, D., Ascah, A., Gains, M., Gardner, B., Mockbee, C., Keutzer, J. M., McManus, J., et al. (2020) · Radiation Research · doi:10.1667/rade-20-00131.1 · Cited by 52
Metadata
- Authors
- Singh, V. K., Newman, V. L., & Seed, T. M.
- Venue
- Cytokine
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 71
- Issue
- 1
- Pages
- 22-37
- ISSN
- 1043-4666 (ISSN-L)
- OpenAlex
- W2069454576
- Cited by
- 121
- References
- 6
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): A review. https://app.cochat.ai/papers/10.1016/j.cyto.2014.08.003
- The paper
- Singh, V. K., Newman, V. L., & Seed, T. M. (2015). Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): A review. Cytokine. https://doi.org/10.1016/j.cyto.2014.08.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.